var title_f6_59_7088="Diagnosis and treatment of intestinal ischemia II";
var content_f6_59_7088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment of intestinal ischemia II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 740px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate accepted management plan; dashed lines indicate alternate management plan.",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Brandt, LJ, Boley, SJ, Gastroenterology 2000; 118:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7088=[""].join("\n");
var outline_f6_59_7088=null;
var title_f6_59_7089="Aniracetam: International drug information";
var content_f6_59_7089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aniracetam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ampamet (IT);",
"     </li>",
"     <li>",
"      Conectol (AR);",
"     </li>",
"     <li>",
"      Draganon (IT, JP);",
"     </li>",
"     <li>",
"      Pergamid (AR);",
"     </li>",
"     <li>",
"      Reset (IT);",
"     </li>",
"     <li>",
"      Sarpul (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Nootropic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Attention and memory disorders of a degenerative or vascular origin in the elderly",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 1500 mg/day in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Granules [sachet]: 750 mg, 1500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 750 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10528 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7089=[""].join("\n");
var outline_f6_59_7089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304146\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977738\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977741\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977737\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821200\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977740\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10528|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_59_7090="Iodinated I-131 albumin: Drug information";
var content_f6_59_7090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iodinated I-131 albumin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/25/2451?source=see_link\">",
"    see \"Iodinated I-131 albumin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13185715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Megatope;",
"     </li>",
"     <li>",
"      Volumex HSA I-131",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13182677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13182870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     To minimize radioactive iodine uptake by the thyroid gland, thyroid protective agents (eg, Lugol's solution, potassium iodide) may be administered 24 hours prior to administration of iodinated I 131 albumin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cardiac output determination:",
"     </b>",
"     I.V.: 3-50 microcuries",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cardiac and pulmonary blood volumes and circulation times:",
"     </b>",
"     I.V.: 75&ndash;130 microcuries",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Heart and great vessel delineation:",
"     </b>",
"     I.V.: 3-5 microcuries",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Localization of cerebral neoplasms:",
"     </b>",
"     I.V.: 5 microcuries/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Protein turnover studies:",
"     </b>",
"     I.V.: 10&ndash;150 microcuries",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13182685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For the determination of total blood and plasma volumes, cardiac output, cardiac and pulmonary blood volumes and circulation times; and in protein turnover studies, heart and great vessel delineation, localization of the placenta, and localization of cerebral neoplasms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13255253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13182881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13182700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Cisternography: Aseptic meningeal irritation and hyperpyrexia have been reported following use in cisternography. Iodinated I 131 albumin is not approved for use in cisternography.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13182699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13182705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13182721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13182722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown whether or not iodinated I 131 albumin enters breast milk; however, free I-131 (eg, from metabolism/deiodination of the product) is excreted in breast milk. Therefore, the patient must be instructed to completely cease breast-feeding for the infant (U.S. Nuclear Regulatory Commission, 1977).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Nuclear Regulatory Commission, \"Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,\" 1977.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16802 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7090=[""].join("\n");
var outline_f6_59_7090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185715\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182677\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182870\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182685\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255253\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182881\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182700\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182699\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182705\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182721\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182722\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16802|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/25/2451?source=related_link\">",
"      Iodinated I-131 albumin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_59_7091="Patient information: Starting solid foods with babies (The Basics)";
var content_f6_59_7091=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15900\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"         Hives",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/27/35250\">",
"         Patient information: Food allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/27/4531\">",
"         Patient information: Weaning from breastfeeding (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/47/29429\">",
"         Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/32/41476\">",
"         Patient information: Starting solid foods during infancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Starting solid foods with babies (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/starting-solid-foods-with-babies-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29147680\">",
"      <span class=\"h1\">",
"       When should I start feeding my baby solid foods?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most doctors recommend that parents start feeding their baby solid foods at about 4 to 6 months old.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147687\">",
"      <span class=\"h1\">",
"       How can I tell if my baby is ready for solid foods?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Babies are usually ready to start eating solid foods when they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Can sit up with help",
"       </li>",
"       <li>",
"        Have good control of their head and neck",
"       </li>",
"       <li>",
"        Put toys or hands in their mouth",
"       </li>",
"       <li>",
"        Show an interest in food by leaning forward and opening their mouth when it&rsquo;s time to eat",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147694\">",
"      <span class=\"h1\">",
"       Which food should I start with?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Start with a food that has only 1 ingredient and is mashed up well. Most parents start with baby cereal, fruits, vegetables, or meats.",
"     </p>",
"     <p>",
"      You can mix baby cereal with breast milk, formula, or water. Make the mixture thin at first, and use a spoon to feed it to your baby. Doctors do not usually recommend putting baby cereal in a baby&rsquo;s bottle.",
"     </p>",
"     <p>",
"      When you start feeding your baby solid foods, give your baby 1 new food every few days. That way, you can make sure that your baby doesn&rsquo;t have an allergy to that food. After a few days, you can try another food.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147701\">",
"      <span class=\"h1\">",
"       How do I know if my baby has an allergy to a food?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your baby might have an allergy to a food if he or she eats it and then has 1 or more of the following symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Skin rash or raised, red patches of skin that are usually very itchy (called hives) (",
"        <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Swollen lips or face",
"       </li>",
"       <li>",
"        Vomiting or diarrhea",
"       </li>",
"       <li>",
"        Coughing or trouble breathing",
"       </li>",
"       <li>",
"        Pale skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Call your doctor or nurse if your child has any of these symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147708\">",
"      <span class=\"h1\">",
"       Can I use baby food from a jar?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, but be sure to follow the instructions about how long the food keeps after the jar is opened. Baby food usually keeps for 2 to 3 days after a jar is opened. If a jar has been opened for more than 3 days, you should throw it out.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147715\">",
"      <span class=\"h1\">",
"       Can I make my own baby food?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, but don&rsquo;t add salt or sugar to it. Babies don&rsquo;t need extra salt or sugar in their food.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147722\">",
"      <span class=\"h1\">",
"       Which foods should I give my baby next?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After you give your baby different foods with only 1 ingredient, move on to foods with 2 or more ingredients. Over time, you can give your baby foods that are thicker and have small chunks in them. That way, your baby can get used to different foods and learn to chew pieces of food.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147729\">",
"      <span class=\"h1\">",
"       Are there foods that babies should not eat or drink?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Babies younger than 1 year old should not drink cow&rsquo;s milk or eat honey.",
"     </p>",
"     <p>",
"      Doctors also recommend that children younger than 4 years old not eat certain foods that commonly cause choking. These foods include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hot dogs",
"       </li>",
"       <li>",
"        Peanuts and other nuts",
"       </li>",
"       <li>",
"        Grapes",
"       </li>",
"       <li>",
"        Raw carrots",
"       </li>",
"       <li>",
"        Popcorn",
"       </li>",
"       <li>",
"        Hard candies",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147736\">",
"      <span class=\"h1\">",
"       Can I give my baby juice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can give your baby juice in a cup at about 6 months old. But do not give your child more than 4 to 6 ounces of juice a day. Drinking more than that can lead to diarrhea, cavities, and other problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147743\">",
"      <span class=\"h1\">",
"       Does my child need vitamins?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors recommend that all babies who breastfeed get daily vitamin D drops starting when they are a few days old. Vitamin D helps bones grow strong. Babies who drink formula might also need vitamin D drops, depending on how much formula they drink each day.",
"     </p>",
"     <p>",
"      Some babies need other vitamins each day, depending on what they eat and other factors. Ask your doctor or nurse if your baby should take vitamins and which ones he or she needs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147750\">",
"      <span class=\"h1\">",
"       When can babies feed themselves?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Babies can usually start picking up pieces of food to feed themselves at about 8 to 10 months old.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29147757\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/27/4531?source=see_link\">",
"       Patient information: Weaning from breastfeeding (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=see_link\">",
"       Patient information: Food allergy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"       Patient information: Starting solid foods during infancy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/59/7091?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15900 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7091=[""].join("\n");
var outline_f6_59_7091=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147680\">",
"      When should I start feeding my baby solid foods?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147687\">",
"      How can I tell if my baby is ready for solid foods?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147694\">",
"      Which food should I start with?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147701\">",
"      How do I know if my baby has an allergy to a food?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147708\">",
"      Can I use baby food from a jar?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147715\">",
"      Can I make my own baby food?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147722\">",
"      Which foods should I give my baby next?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147729\">",
"      Are there foods that babies should not eat or drink?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147736\">",
"      Can I give my baby juice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147743\">",
"      Does my child need vitamins?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147750\">",
"      When can babies feed themselves?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29147757\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15900\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"      Hives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=related_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=related_link\">",
"      Patient information: Starting solid foods during infancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/27/4531?source=related_link\">",
"      Patient information: Weaning from breastfeeding (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_59_7092="Potassium citrate (tablet): Drug information";
var content_f6_59_7092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium citrate (tablet): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/35/32308?source=see_link\">",
"    see \"Potassium citrate (tablet): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Urocit&reg;-K",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Urocit&reg;-K",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkalinizing Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Alkalinizer, bicarbonate precursor:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate hypocitraturia (&gt;150 mg urinary citrate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release: 10 mEq 3 times daily; maximum dose: 100 mEq/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release: 15 mEq 2 times daily",
"     <b>",
"      or",
"     </b>",
"     10 mEq 3 times daily; maximum dose: 100 mEq/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hypocitraturia (&lt;150 mg/day urinary citrate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release: 20 mEq 3 times daily",
"     <b>",
"      or",
"     </b>",
"     15 mEq 4 times daily; maximum dose: 100 mEq/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release: 30 mEq 2 times daily",
"     <b>",
"      or",
"     </b>",
"     20 mEq 3 times daily; maximum dose: 100 mEq/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 540 mg, 1080 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urocit&reg;-K: 540 mg [5 mEq]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urocit&reg;-K: 1080 mg [10 mEq]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urocit&reg;-K: 1620 mg [15 mEq]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals or bedtime snack (or within 30 minutes after). Swallow tablets whole with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of uric acid nephrolithiasis; prevention of calcium renal stones in patients with hypocitraturia; urinary alkalinizer when sodium citrate is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F211891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Urocit&reg;-K may be confused with Urised",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe renal insufficiency; patients with hyperkalemia or with conditions predisposing to hyperkalemia (eg, acute dehydration, adrenal insufficiency, uncontrolled diabetes mellitus,  tissue breakdown, concurrent use of potassium-sparing agents); patients with delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication; patients with active urinary tract infection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI effects: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation and/or obstruction. Oral liquid preparations (not solid) should be used in patients with esophageal compression or delayed gastric emptying.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Citrate is converted to bicarbonate in the liver; this conversion may be blocked in patients in hepatic failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (eg, untreated Addison's disease, heat cramps, severe tissue breakdown from trauma or burns).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Contraindicated with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Severely ill: Citrate is converted to bicarbonate in the liver; this conversion may be blocked in patients who are severely ill or in shock.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digitalis: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACEI, potassium-sparing diuretics, potassium containing salt substitutes).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13892559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F211880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13892560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium is excreted into breast milk. The normal potassium ion content of human milk is ~13 mEq/L. It is not known if this product may affect normal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F211867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate fluid intake; limit salt intake. Take with meals or snack.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Potassium Citrate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 MEQ (540 MG) (100): $127.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 MEQ (1080 MG) (100): $178.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Urocit-K 10 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 MEQ (1080 MG) (100): $111.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Urocit-K 15 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 MEQ (1620 mg) (100): $180.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Urocit-K 5 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 MEQ (540 MG) (100): $79.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11563766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes (potassium, chloride, sodium), bicarbonate, serum creatinine, and CBC every 4 months (more frequently with cardiac/renal disease or acidosis); urinary citrate and/or urinary pH at initiation or dose change and every 4 months; ECG (periodically)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13203098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Urinary pH: 4.6-8.0",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F211868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acelka (TH);",
"     </li>",
"     <li>",
"      Citro-K (CO);",
"     </li>",
"     <li>",
"      K-Cit (PH);",
"     </li>",
"     <li>",
"      Kajos (NO, SE);",
"     </li>",
"     <li>",
"      Kalium granulat bezcukrowy (PL);",
"     </li>",
"     <li>",
"      Kation (IT);",
"     </li>",
"     <li>",
"      Litocid (PL);",
"     </li>",
"     <li>",
"      Tascit (PH);",
"     </li>",
"     <li>",
"      Urocit (EC);",
"     </li>",
"     <li>",
"      Urocit-K (AU, BR, HK, MY, SG, TW);",
"     </li>",
"     <li>",
"      Urocitra-K SR (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metabolism: Hepatic to bicarbonate",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10225 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7092=[""].join("\n");
var outline_f6_59_7092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211872\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211873\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211887\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211875\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211876\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211861\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211849\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211863\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211862\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211891\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211885\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211866\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211852\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299919\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222462\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211857\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892559\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211880\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892560\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211867\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524691\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11563766\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203098\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211868\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211865\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10225|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/35/32308?source=related_link\">",
"      Potassium citrate (tablet): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_59_7093="Triprolidine and pseudoephedrine: Pediatric drug information";
var content_f6_59_7093=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triprolidine and pseudoephedrine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/40/35462?source=see_link\">",
"    see \"Triprolidine and pseudoephedrine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/13/18645?source=see_link\">",
"    see \"Triprolidine and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aprodine [OTC];",
"     </li>",
"     <li>",
"      Pediatex&reg; TD;",
"     </li>",
"     <li>",
"      Silafed [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Actifed&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine/Decongestant Combination",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/40/35462?source=see_link\">",
"      see \"Triprolidine and pseudoephedrine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;2 years: May dose according to",
"     <b>",
"      pseudoephedrine",
"     </b>",
"     component: 4 mg/kg/day in divided doses 3-4 times/day not to exceed a maximum of 60 mg pseudoephedrine per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: Pediatex&reg; TD: 1.33 mL every 6 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: Pediatex&reg; TD: 2.67 mL every 6 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup (Aprodine):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: 5 mL every 4-6 hours; do not exceed 4 doses in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 10 mL every 4-6 hours; do not exceed 4 doses in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet (Aprodine):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet every 4-6 hours; do not exceed 4 doses in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years and Adults: One tablet every 4-6 hours; do not exceed 4 doses in 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatex&reg; TD: Triprolidine hydrochloride 0.938 mg and pseudoephedrine hydrochloride 10 mg per 1 mL (30 mL) [cotton candy flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: Triprolidine hydrochloride 1.25 mg and pseudoephedrine hydrochloride 30 mg per 5 mL (120 mL) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aprodine: Triprolidine hydrochloride 1.25 mg and pseudoephedrine hydrochloride 30 mg per 5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silafed: Triprolidine hydrochloride 1.25 mg and pseudoephedrine hydrochloride 30 mg per 5 mL (120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aprodine: Triprolidine hydrochloride 2.5 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or milk to decrease GI irritation",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of nasal congestion, running nose, sneezing, itching of nose or throat and itchy, watery eyes due to common cold, hay fever or other upper respiratory allergies (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14188080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F231817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, fatigue, headache, insomnia, nervousness, transient stimulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite increase, diarrhea, nausea, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis, thickening of bronchial secretions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triprolidine, pseudoephedrine, or any component; severe hypertension or coronary artery disease; MAO inhibitor therapy, GI or GU obstruction, narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with mild to moderate high blood pressure, heart disease, diabetes mellitus, asthma, thyroid disease, or prostatic hypertrophy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects including death have been reported. The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14456831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal antihistamine use has generally not resulted in an increased risk of birth defects; however, information related to triprolidine is limited. Refer to the pseudoephedrine monograph for information related to decongestants.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/13/18645?source=see_link\">",
"      see \"Triprolidine and pseudoephedrine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12866 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E9068B15A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7093=[""].join("\n");
var outline_f6_59_7093=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231800\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231801\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062784\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062779\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231793\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231781\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062788\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062787\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14188080\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231817\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062790\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062778\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062777\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231810\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231789\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456831\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062783\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12866\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12866|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/40/35462?source=related_link\">",
"      Triprolidine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/13/18645?source=related_link\">",
"      Triprolidine and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_59_7094="Fixed cutaneous sporotrichosis";
var content_f6_59_7094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fixed cutaneous sporotrichosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fungating lesion on upper limb (hand).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: da Rosa, AC, Scroferneker, ML, Vettorato, R, et al. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52:451. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7094=[""].join("\n");
var outline_f6_59_7094=null;
var title_f6_59_7095="Miliaria crystallina vesicles";
var content_f6_59_7095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Miliaria crystallina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple&nbsp;small vesicles are present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7095=[""].join("\n");
var outline_f6_59_7095=null;
var title_f6_59_7096="Reuse of dialyzers";
var content_f6_59_7096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reuse of dialyzers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/59/7096/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7096/contributors\">",
"     Doug Schram, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7096/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7096/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/59/7096/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7096/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/59/7096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7096/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/59/7096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first description of hemodialyzer reuse appeared in 1964 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/1\">",
"     1",
"    </a>",
"    ]. Since that time, emphasis on cost containment, development of costlier but more efficient membranes, and improvements in reprocessing techniques led to a high rate of dialyzer reuse in the United States. According to a 1992 annual report from the Centers for Disease Control (CDC), 72 percent of surveyed chronic hemodialysis units in the United States reprocessed dialyzers regularly, affecting 78 percent of hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, the incidence of reuse has largely decreased in frequency. In 2005, for example, approximately 40 percent of dialysis units in the United States were thought to reusing dialyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is due in part to the effort by Fresenius Medical Care-North America to abandon reuse by mass-producing a favorably priced dialyzer with similar performance characteristics to popular reusable dialyzers. With the acquisition of Renal Care Group, these events have resulted in a significant decrease in dialyzer reuse in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of guidelines have emerged to ensure safety and effectiveness of the reprocessing procedure. The Association for the Advancement of Medical Instrumentation (AAMI) has published recommendations for dialyzer reprocessing techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/5\">",
"     5",
"    </a>",
"    ]. The Health Care Financing Administration (HCFA) requires all dialysis centers that reprocess dialyzers to comply with the AAMI guidelines as a condition for reimbursement. Additional regulations may be imposed by city, county, or state health departments.",
"   </p>",
"   <p>",
"    Hemodialyzers are labeled by the Food and Drug Administration as single use only. In recognition of the widespread practice of reuse in the United States, in 1996 the FDA required manufacturers to label dialyzers for multiple use and to back up this claim with data showing that the performance of the dialyzer is sustained over multiple uses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REPROCESSING TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;After use, dialyzers may be reprocessed manually or with the use of automated equipment. The automated method is probably somewhat more reliable and predictable. An initial study found higher mortality rates in hemodialysis units using a peroxyacetic",
"    <span class=\"nowrap\">",
"     acid/",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"      hydrogen peroxide",
"     </a>",
"    </span>",
"    mixture (PAM) when combined with manual reprocessing techniques but not with automated techniques. However, a follow-up study by the same authors using a very large number of patients did not show a significant difference in mortality between processing techniques when using identical germicides [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/6\">",
"     6",
"    </a>",
"    ]. (See Reuse effects on patient mortality below).",
"   </p>",
"   <p>",
"    The basic procedure for dialyzer reprocessing involves four steps: rinsing, cleaning, performance testing, and disinfection and sterilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rinsing",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the termination of dialysis, the dialyzer is rinsed and filled with saline while still at the dialysis machine. It is then reprocessed within two hours or refrigerated if reprocessing is delayed. At reprocessing, the dialyzer is flushed with pressurized dialysis-quality water. Removal of residual blood may be enhanced by reverse ultrafiltration. Some centers use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    in the rinsing procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cleaning",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAM (Renalin&trade;) is a common agent used to clean dialyzers. One percent (or less) sodium hypochlorite (bleach) can also be used but this agent has several",
"    <strong>",
"     disadvantages",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It removes protein deposits that confer",
"      <strong>",
"       biocompatibility",
"      </strong>",
"      to bioincompatible membranes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9911?source=see_link\">",
"       \"Biochemical mechanisms involved in blood-hemodialysis membrane interactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It may damage the membrane and increase the ultrafiltration coefficient [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bleach-processed polysulfone dialyzers may leak substantial quantities of protein; the degree of protein loss increases with an increasing number of reuses. In one study, for example, an average of 6.6 grams of protein was lost during the dialysis after 12 to 15 reuses, while 16.7 grams was lost with 23 to 30 reuses [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/8\">",
"       8",
"      </a>",
"      ]. When bleach was removed from the reprocessing routine, protein loss fell in association with an elevation in the plasma albumin concentration from 3.55 to 3.79",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (35.5 to 37.9",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      over a six month period. Whether these findings apply to bleach processing of other dialyzers is not known. Some manufacturers of polysulfone membrane dialyzers have developed membranes less sensitive to the adverse effects of bleach reprocessing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Performance testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A blood path integrity test is performed to check for leaks in the dialyzer casing, membrane, and supporting materials. Pressurized air, nitrogen, or reverse osmosis water is pumped into the blood side and negative pressure is applied to the dialysate side of the membrane. A drop in the pressure gradient indicates membrane leakage.",
"   </p>",
"   <p>",
"    The fiber bundle volume (FBV) is the total fluid volume contained on the blood side of the membrane and is an indirect estimate of dialyzer clearance. The FBV is measured by filling the blood compartment of the dialyzer with fluid and then forcing air or nitrogen into the blood compartment and measuring the volume or weight of expelled fluid. The maximum allowable decrease in FBV is",
"    <strong>",
"     20 percent",
"    </strong>",
"    of the original value, correlating to a 10 percent decrease in urea clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These data were derived from the use of cellulosic dialyzers. No such work has been corroborated with modern dialyzers.",
"   </p>",
"   <p>",
"    Another method to estimate urea clearance during reprocessing is the in vitro ultrafiltration coefficient (Kuf). This is measured by determining the volume of water passing through the membrane at a given temperature and pressure.",
"   </p>",
"   <p>",
"    However, the FBV measured with in vitro methods (on the reprocessing machine when the dialyzer is disconnected from the patient) may differ from the FBV present in vivo (during actual dialysis), due principally to flushing of clot out of the fibers, which occurred prior to disconnection from the patient. One study utilized two in vivo indicator methods, ultrasound detection of the dilution of a saline bolus or a step change in ultrafiltration and the subsequent change in blood",
"    <span class=\"nowrap\">",
"     concentration/density",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/11\">",
"     11",
"    </a>",
"    ]. Both techniques were validated and found to be reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/11\">",
"     11",
"    </a>",
"    ]. In six patients, the FBV decreased by more than 10 percent as measured by in vivo techniques, while in vitro measurements revealed an increase of approximately 1 percent. Thus, in vitro FBV may not accurately reflect the true intradialytic FBV and effective surface area. This finding again emphasizes why the actual measurement of delivered dialysis dose is so important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Disinfection and sterilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germicides are instilled into the blood and dialysate compartments before final inspection and storage. The most commonly used germicide is PAM (4.5 percent peroxyacetic acid, 28 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    ) but four percent formaldehyde or 0.8 percent glutaraldehyde (a derivative of formaldehyde) can also be used.",
"   </p>",
"   <p>",
"    A different method of sterilization is to fill the dialyzer with dialysis-quality water after cleaning and place it in a 105&ordm;C convection oven for 20 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/12\">",
"     12",
"    </a>",
"    ]. This procedure has the advantages of eliminating staff and patient exposure to germicides. However, it can only be used for polysulfone dialyzers and may not yield as many reuses. Another option is to use a lower concentration of formaldehyde (0.7 to 1.0 percent) in combination with heating to between 95&ordm; and 110&ordm;F.",
"   </p>",
"   <p>",
"    The heat disinfection process has been modified by the addition of 1.5 percent citric acid [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/12\">",
"     12",
"    </a>",
"    ]. This change has allowed lower temperatures to be used (95&ordm;C), thereby reducing thermal stress on the dialyzer; it also avoids the use of germicides.",
"   </p>",
"   <p>",
"    In a survey of dialysis units performed in 2002, the following were the percentage of centers using the various methods for reprocessing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peractic acid product (72 percent)",
"     </li>",
"     <li>",
"      Formaldehyde (20 percent)",
"     </li>",
"     <li>",
"      Heat (4 percent)",
"     </li>",
"     <li>",
"      Glutaraldehyde (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Care must be taken in the removal of germicides and in the proper labeling of individual dialyzers to make certain that cross-usage does not occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RATE OF REUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of reuses from a single dialyzer varies widely among patients and dialysis units. The CDC reported that the median number of reuses nationally was 14, with a maximum median number of reuses of 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dialyzer clotting is a common factor underlying poor performance with reuse, resulting in an enhanced frequency of discarded dialyzers. The adoption of an improved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dosing regimen with routine dialysis may increase the rate of reuse. In one study of 44 chronic hemodialysis patients, the use of a mathematical model system that determined the optimal heparin loading dose and infusion rate (to attain a whole-blood intradialytic clotting time of 150 percent of the predialysis level) significantly increased dialyzer reuse rates among the modeled, but not control, patient group [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/15\">",
"     15",
"    </a>",
"    ]. There were no changes in the incidence of bleeding complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL CONSIDERATIONS WITH DIALYZER REUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major concerns with reuse: the risk of infection; biochemical and immunologic effects; and loss of performance with impairment in clearance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrafiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infection risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is at present no evidence that dialyzer reuse is associated with viral hepatitis or HIV transmission to patients or dialysis personnel if appropriate guidelines are followed. To minimize any risk, dialyzers should be handled with universal precautions and dialyzers from hepatitis B surface antigen-positive patients should be reprocessed and stored in a separate area. Dialyzers from patients with sepsis or acute hepatitis should not be reused. In comparison, there are no CDC recommendations against dialyzer reuse in hepatitis C or HIV infected patients. However, many physicians absolutely oppose reuse in any patient known to be infected with these organisms.",
"   </p>",
"   <p>",
"    Pyrogenic dialyzer reactions are manifested by fever, chills, myalgias, nausea and hypotension. These reactions can occur when endotoxins (usually from a contaminated water supply) enter the bloodstream. In addition, nontuberculous mycobacteria are frequently found in tap water and are much more resistant to chlorine than Pseudomonas aeruginosa and other gram-negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/16\">",
"     16",
"    </a>",
"    ]. Mycobacteria resistant to two percent formaldehyde have been isolated from as many as 83 percent of dialysis unit water samples [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/17\">",
"     17",
"    </a>",
"    ] and deaths in two dialysis units have been attributed to dialysis-acquired Mycobacterium chelonei infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/16\">",
"     16",
"    </a>",
"    ]. Since these outbreaks, the CDC has recommended the use of four percent formaldehyde for at least 48 hours during reprocessing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several comparative and double-blind randomized clinical trials have not shown an increased risk of pyrogenic reactions with dialyzer reuse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. These findings implicate a contaminated water supply as the cause of the pyrogenic reaction. Contaminated water used in the reprocessing of a dialyzer can contaminate the dialyzer even in the presence of germicides because bacteria can be trapped in areas where the germicide cannot penetrate. Pressures generated during dialysis can open the trapped areas, releasing viable bacteria. There may be a greater risk of infection in centers in which the dialyzer headers are removed during reprocessing. Issues concerning water purification are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10775?source=see_link\">",
"     \"Maintaining water quality for hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Biochemical and immune system effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of nonbiocompatible (cellulose-based) membranes is associated with complement activation, leukopenia, leukocyte sequestration with subsequent cytokine release, and dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    .) This cascade may play a role in dialysis-induced hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cuprophane dialyzers can be rendered biocompatible by reuse, an effect that is presumably due to membrane coating by serum proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/25\">",
"     25",
"    </a>",
"    ]. As previously mentioned, removal of the protein coat with bleach will return the membrane to its previous complement-activating state. In one study, cuprophane dialyzers were rendered more biocompatible after reuse, as shown by improvement in peak expiratory flow rate when compared to new cuprophane dialyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/26\">",
"     26",
"    </a>",
"    ]. There is no biological advantage from reusing biocompatible synthetic membranes since these membranes are associated with little or no complement activation.",
"   </p>",
"   <p>",
"    The \"first use\" syndrome is an anaphylactoid IgE-mediated reaction that occurs during the first use of a dialyzer and is most often due to sensitization to ethylene oxide used for sterilization during manufacture [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link&amp;anchor=H3#H3\">",
"     \"Reactions to the hemodialysis membrane\", section on 'Type A reactions'",
"    </a>",
"    .) An argument favoring reuse is that reprocessing a new dialyzer thoroughly removes ethylene oxide. However, this argument is not sound because the incidence of the first use syndrome is extremely low and can be reduced significantly by thorough rinsing of the dialyzer and blood lines before use.",
"   </p>",
"   <p>",
"    There is no clearly documented relationship between complement activation and the first use syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/12,21\">",
"     12,21",
"    </a>",
"    ]; thus, prevention of this syndrome is not a valid reason to reuse dialyzers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The oxidative response of polymorphonuclear cells may be influenced by the type of dialyzer reuse. This was shown in an analysis from the HEMO study in which the use of bleach or renalin as a cleansing agent resulted in higher neutrophil superoxide bursts compared to that observed with aldehydes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/28\">",
"     28",
"    </a>",
"    ]. The clinical implication of these observations is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Loss of performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations have been made after reprocessing dialyzers with bleach and formaldehyde or with PAM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are combinations of membranes and cleaning agents that impair, enhance, or do not affect the removal of &szlig;2-microglobulin [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]. In the HEMO study, for example, the combination of bleach, formaldehyde, and an F80B dialyzer (a high-flux polysulfone membrane) markedly increased the clearance of &szlig;2-microglobulin, while reprocessing the same dialyzer with bleach and PAM only modestly enhanced clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/31\">",
"       31",
"      </a>",
"      ]. Bleach reprocessing can increase inulin and myoglobulin clearance of F80B dialyzers and increase myoglobulin clearance of CT190 dialyzers [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are negligible effects on urea, creatinine, and phosphorus removal with cellulose membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/20\">",
"       20",
"      </a>",
"      ]. However, reprocessing dialyzers may compromise delivery of the prescribed dialysis dose. One report, for example, measured",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      for urea during dialysis with a low (mean fourth reuse) and a high (mean fourteenth reuse) number of reuses [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/33\">",
"       33",
"      </a>",
"      ]. The",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      was significantly lower in the high number reuse treatment (1.05 versus 1.10 early in the sequence). Why this occurs is unclear, but could relate to the progressive intradialytic loss of FBV and effective surface area that is not detected during postdialysis FBV measurements made on the reprocessing machine [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Water permeability (ultrafiltration) may fall slightly after reuse with PAM and increase after reuse with bleach and formaldehyde [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/20,34\">",
"       20,34",
"      </a>",
"      ]. However, any loss of water permeability may have a larger detrimental effect on the convective clearance of middle molecular weight molecules, such as beta-2-microglobulin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommended that reused dialyzers should have either [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood compartment volume at least 80 percent of original measured volume",
"     </li>",
"     <li>",
"      Urea (or ionic) clearance at least 90 percent of original measured clearance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GERMICIDE EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is concern about possible adverse effects to germicide exposure with reuse. Chronic exposure to formaldehyde, for example, has been associated with formation of antibodies to the erythrocyte N-antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The anti-N-like antibodies are first seen 12 to 18 months after first exposure but eventually disappear if the modality of treatment is changed. The clinical importance of these antibodies is unknown, but they have been associated with hemolysis and early transplant failure in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, a test for removal of germicide is routinely performed prior to reuse of the dialyzer. Dialyzers need to be continuously rinsed because of a \"sink\" effect that may lead them to become repositories of the germicide.",
"   </p>",
"   <p>",
"    Another potential complication is an anaphylactoid reaction which, in one study, was documented in 10 patients treated with reprocessed dialyzers sterilized with PAM; these reactions appeared to be more frequent in patients taking angiotensin converting enzyme (ACE) inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/38\">",
"     38",
"    </a>",
"    ]. Cessation of reuse led to resolution of symptoms despite continuation of the ACE inhibitor.",
"   </p>",
"   <p>",
"    Why these reactions occur in selected patients is not clear. One hypothesis is that some patients may have an interaction between a reused dialyzer and ACE inhibition. The latter may act by increasing kinin levels. Angiotensin converting enzyme is also a kininase; as a result, ACE inhibition also inhibits kinin degradation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H8#H8\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Angioedema and anaphylactoid reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General problems with chemical disinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other adverse patient reactions to chemical disinfectants are rare if meticulous techniques are followed. However, there are some additional problems that have occurred with these techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some dialysis staff have developed allergic reactions to formaldehyde which precludes their participation in reuse.",
"     </li>",
"     <li>",
"      Larger formaldehyde spills have occurred, temporarily disrupting dialysis routines.",
"     </li>",
"     <li>",
"      Pyrogenic and (rarely) mycobacterial infection have been related to subtherapeutic levels of peroxyacetic acid and formaldehyde [",
"      <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These general problems have led to the search for other modalities to reprocess dialyzers, including heat disinfection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Heat disinfection of dialyzers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A favorable experience was reported using heat disinfection of Fresenius polysulfone dialyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/39\">",
"     39",
"    </a>",
"    ]. These investigators analyzed their experience in 12,530 treatments in 103 patients; HIV positive but not hepatitis B antigen positive patients were included. Maximum reuse was 10 times, and the dialyzer was rinsed with reverse-osmosis water rather than bleach. They found that bleach caused the dialyzer casing to deteriorate when combined with the heating process. The dialyzers were heated in self-sealing bags in a temperature convection oven to 105&ordm;C for 20 to 36 hours.",
"   </p>",
"   <p>",
"    The reprocessed dialyzers generally performed well. Casing leaks accounted for 36 percent of dialyzer failures, dialyzer leaks for 13 percent, blood leaks for four percent, a decrease in dialyzer bundle volume for five percent, and cosmetic deterioration (retained blood) for two percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors concluded that heat disinfection was a very safe and effective reprocessing technique. It has the significant advantage of avoiding the problems with chemical disinfection noted above. One disadvantage is that the number of reuses with heat disinfection will probably be less than with chemicals, due primarily to casing deterioration of the casing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EFFECTS OF REUSE ON PATIENT MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many observational studies have been performed addressing the relationship between reuse and mortality. Increased, decreased, and no change in mortality have been reported, with some variation due in part to differences in study techniques and periods of study [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/40\">",
"     40",
"    </a>",
"    ]. The following is a survey in temporal sequence of some of the studies that have addressed the issue of patient mortality and reuse.",
"   </p>",
"   <p>",
"    A large study (the Urban Institute study) evaluated the mortality associated with dialyzer reprocessing using PAM or glutaraldehyde compared to formaldehyde or nothing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/6\">",
"     6",
"    </a>",
"    ]. The study was performed to resolve preexisting controversy concerning reuse and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/18,41-43\">",
"     18,41-43",
"    </a>",
"    ]. This study prospectively evaluated two cohorts of patients (66,097 patients from 845 units in 1989 and 857 units in 1990), 81 percent of whom were treated with reprocessed dialyzers. Patient comorbidity was not controlled. The findings of this study related to dialyzer reuse can be summarized as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/6\">",
"     6",
"    </a>",
"    ]. For low-flux dialyzers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When compared to patients who did not reuse, overall mortality was increased by 13 percent with the use of PAM (p&lt;.001) and 17 percent with the use of glutaraldehyde (p = 0.01). However, different findings were noted in the subset of hospital-based outpatient units using low-flux dialyzers in which mortality was lower with PAM reuse and unchanged with glutaraldehyde reuse compared to nonreuse hospital units. Thus, the germicidal agent is not the only issue and, by implication, the quality of the reprocessing technique may contribute to increased mortality.",
"     </li>",
"     <li>",
"      There was no increase in mortality associated with the use of formaldehyde.",
"     </li>",
"     <li>",
"      PAM was associated with a higher mortality whether manual (relative risk = 1.14) or automated (relative risk = 1.12) reprocessing techniques were used.",
"     </li>",
"     <li>",
"      The use of PAM was associated with an 11 percent increase in hospitalization rates.",
"     </li>",
"     <li>",
"      Mortality rose 29 percent in units switching from formaldehyde to glutaraldehyde when compared to units that did not switch. There was no statistically significant rise with a switch to PAM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results were quite different with high-flux dialyzers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the few units that used predominantly high-flux dialyzers without reuse, the mortality rate was lower than or similar to the reference group of non-reused low-flux dialyzers.",
"     </li>",
"     <li>",
"      Mortality was somewhat lower in units reusing high-flux dialyzers with PAM (relative risk = 0.89) or glutaraldehyde (relative risk = 0.79) and similar with formaldehyde (relative risk = 0.98) when compared to units using nonreprocessed low-flux dialyzers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comparable observations were described in another report that relied upon a similar",
"    <span class=\"nowrap\">",
"     HCFA/CDC",
"    </span>",
"    database and some of the same patient files as the Urban Institute study mentioned above [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/44\">",
"     44",
"    </a>",
"    ]. This report, however, did not evaluate the effect of high or low flux dialyzers. The survival of patients was evaluated based upon whether they were treated in free-standing or hospital based dialysis units in which dialyzers were either reused with several germicides or were not reused. In this study, reuse with PAM in free standing units (but not in hospital-based units) was associated with a higher mortality than was reuse with formaldehyde or no reuse.",
"   </p>",
"   <p>",
"    A third report utilized a similar database as the Urban Institute study [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/6\">",
"     6",
"    </a>",
"    ], but extended the analysis into the period 1991 to 1993 and considered additional variables, including the effects of freestanding versus hospital-based dialysis facilities and the unique characteristics of each unit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/45\">",
"     45",
"    </a>",
"    ]. Using a sophisticated statistical analysis, mortality appeared to be inconsistently associated with reuse practices. The authors concluded that factors other than reuse, such as the type of dialysis therapy and nutritional status, underlie variations in mortality observed in dialysis patients.",
"   </p>",
"   <p>",
"    An accompanying editorial, however, pointed out that the conclusions derived from such databases in this and related studies are unreliable because of multiple problems, including selection bias, global inferences drawn from unit-level data, and poorly characterized or unknown center effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/46\">",
"     46",
"    </a>",
"    ]. Another study, for example, reported no reuse-associated mortality when the impact of dialysis unit characteristics and disease severity were adequately assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the most detailed report from the USRDS in which demographic variables, comorbidities and facility confounders were controlled, many of the mortality risks associated with some reuse practices were far less evident [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/48\">",
"     48",
"    </a>",
"    ]. This result was almost certainly due to the improved quality control of reuse practices prompted by earlier reports, as well as a significant increase in use of synthetic membranes. The benefits of bleach in the reprocessing of synthetic high flux dialyzers have also been observed.",
"   </p>",
"   <p>",
"    Analysis of nearly 50,000 incident hemodialysis patients in the 1998 to 1999 period, with follow-up through the end of the year 2000, found that reuse practices had",
"    <strong>",
"     no",
"    </strong>",
"    effect on survival [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/49\">",
"     49",
"    </a>",
"    ]. The authors thought that this result may have been due to consistency of care related to the NKF task force position paper published in 1997 (as delineated in the next section).",
"   </p>",
"   <p>",
"    By comparison, another study found a possible long-term survival advantage with single use versus reuse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/50\">",
"     50",
"    </a>",
"    ]. However, methodologic problems limit these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest observational study evaluated the impact of reuse among 75,831 patients, of whom 61,391 were on reuse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients who initiated therapy from January 2000 to December 2001 were analyzed and followed to December 31, 2002. After adjustment for chain affiliation, for-profit status, year of dialysis inception, age, sex, race, renal diagnosis, comorbidity, and hospitalization days, mortality was the same for reuse or no reuse in both an intent-to-treat and as-treated approach.",
"   </p>",
"   <p>",
"    A large US dialysis organization performed a sophisticated analysis of patient survival in its centers performing re-use&nbsp;in a standardized manner (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , peroxyacetic acid, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/53\">",
"     53",
"    </a>",
"    ]. A time dependent survival analysis suggested a slight survival advantage with such re-use, which may have been neutralized by a high number of reuses. Nonetheless, re-use was not associated with an increased mortality and led to significant reduction in high risk medical waste.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NKF TASK FORCE POSITION PAPER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Kidney Foundation (NKF) published a position paper on reuse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7096/abstract/54\">",
"     54",
"    </a>",
"    ]. The task force took no position concerning whether dialyzers should or should not be reused. It was recognized that the driving force behind dialyzer reuse is the associated cost-savings.",
"   </p>",
"   <p>",
"    The following recommendations and conclusions were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A full discussion should be undertaken with the patient concerning the benefits, hazards, and issues relating to reuse.",
"     </li>",
"     <li>",
"      Further investigation is required to accurately assess the morbidity and mortality associated with reuse.",
"     </li>",
"     <li>",
"      A measurement of dialysis adequacy, such as",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      for urea or the urea reduction ratio, should be performed at least monthly. To compensate for any possible loss of dialyzer efficiency with reuse, units utilizing reuse should design dialysis prescriptions that deliver a",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      for urea or a urea reduction ratio which exceeds the dose for patients treated with single-use dialyzers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We make the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, dialyzer reuse appears to be a safe and cost effective procedure for high-flux and high-urea removal dialyzers. Furthermore, reprocessing these relatively more expensive dialyzers (although much less costly than in the past) may ensure their availability to more patients and have a positive impact on patient morbidity and mortality in the future.",
"     </li>",
"     <li>",
"      There is limited, if any, need to dialyze with low-flux, low urea clearance dialyzers. Reuse of such dialyzers may be associated with an increase in mortality, which may be due in part to deterioration in dialyzer performance that is already low prior to reuse.",
"     </li>",
"     <li>",
"      The use of heat disinfection as an alternative to the chemical process is promising and is deserving of more study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no federal laws requiring informed patient consent before reusing a dialyzer, although in practice it is usually obtained. As recommended by the National Kidney Foundation (NKF) task force (see above), each patient should be informed of the potential risks and advantages of dialyzer reuse and given an active role in ensuring that the correct dialyzer is in place before hemodialysis begins.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/1\">",
"      ROSEN SM, O'CONNOR K, SHALDON S. HAEMODIALYSIS DISEQUILIBRIUM. Br Med J 1964; 2:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/2\">",
"      Tokars JI, Alter MJ, Favero MS, et al. National surveillance of dialysis associated diseases in the United States, 1992. ASAIO J 1994; 40:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/3\">",
"      Lacson E Jr, Lazarus JM. Dialyzer best practice: single use or reuse? Semin Dial 2006; 19:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/4\">",
"      Upadhyay A, Sosa MA, Jaber BL. Single-use versus reusable dialyzers: the known unknowns. Clin J Am Soc Nephrol 2007; 2:1079.",
"     </a>",
"    </li>",
"    <li>",
"     Recommended practice for reuse of hemodialyzers. Arlington, VA, AAMI 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/6\">",
"      Held PJ, Wolfe RA, Gaylin DS, et al. Analysis of the association of dialyzer reuse practices and patient outcomes. Am J Kidney Dis 1994; 23:692.",
"     </a>",
"    </li>",
"    <li>",
"     Pizziconi, VB. Performance and integrity testing in reprocessed dialyzers: A QC update. AAMI, Standards and Recommended Practices, Vol 3, Dialysis, Association for the Advancement of Medical Instrumentation, Arlington, 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/8\">",
"      Kaplan AA, Halley SE, Lapkin RA, Graeber CW. Dialysate protein losses with bleach processed polysulphone dialyzers. Kidney Int 1995; 47:573.",
"     </a>",
"    </li>",
"    <li>",
"     Kaufman, AM, Godmere, RO, et al. Dialyzer reuse. In: Handbook of Dialysis, 2d ed, Daugirdas, JT, Ing, TS (Eds), Little, Brown, Boston, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/10\">",
"      Gotch FA. Mass transport in reused dialyzers. Proc Clin Dial Transplant Forum 1980; 10:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/11\">",
"      Krivitski NM, Kislukhin VV, Snyder JW, et al. In vivo measurement of hemodialyzer fiber bundle volume: theory and validation. Kidney Int 1998; 54:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/12\">",
"      Kaufman AM, Frinak S, Godmere RO, Levin NW. Clinical experience with heat sterilization for reprocessing dialyzers. ASAIO J 1992; 38:M338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/13\">",
"      Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/14\">",
"      Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J 1998; 44:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/15\">",
"      Ouseph R, Brier ME, Ward RA. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis 2000; 35:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/16\">",
"      Bolan, G, Reingold, AI, et al. Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J Infect Dis 1985; 152:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/17\">",
"      Bland L, Alter M, Favero M, et al. Hemodialyzer reuse: practices in the United States and implication for infection control. Trans Am Soc Artif Intern Organs 1985; 31:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/18\">",
"      Kant KS, Pollak VE, Cathey M, et al. Multiple use of dialyzers: safety and efficacy. Kidney Int 1981; 19:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/19\">",
"      Bok DV, Pascual L, Herberger C, et al. Effect of multiple use of dialyzers on intradialytic symptoms. Proc Clin Dial Transplant Forum 1980; 10:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/20\">",
"      Fleming SJ, Foreman K, Shanley K, et al. Dialyser reprocessing with Renalin. Am J Nephrol 1991; 11:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/21\">",
"      Churchill DN, Taylor DW, Shimizu AG, et al. Dialyzer re-use--a multiple crossover study with random allocation to order of treatment. Nephron 1988; 50:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/22\">",
"      Chenoweth DE, Cheung AK, Ward DM, Henderson LW. Anaphylatoxin formation during hemodialysis: comparison of new and re-used dialyzers. Kidney Int 1983; 24:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/23\">",
"      Stroncek DF, Keshaviah P, Craddock PR, Hammerschmidt DE. Effect of dialyzer reuse on complement activation and neutropenia in hemodialysis. J Lab Clin Med 1984; 104:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/24\">",
"      Shusterman NH, Feldman HI, Wasserstein A, Strom BL. Reprocessing of hemodialyzers: a critical appraisal. Am J Kidney Dis 1989; 14:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/25\">",
"      Dumler, F. Reuse of hemodialyzers. Semin Dial 1994; 7:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/26\">",
"      Davenport A, Williams AJ. The effect of dialyzer reuse on peak expiratory flow rate. Respir Med 1990; 84:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/27\">",
"      Bommer J, Ritz E. Ethylene oxide (ETO) as a major cause of anaphylactoid reactions in dialysis (a review). Artif Organs 1987; 11:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/28\">",
"      Rao M, Guo D, Jaber BL, et al. Dialyzer membrane type and reuse practice influence polymorphonuclear leukocyte function in hemodialysis patients. Kidney Int 2004; 65:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/29\">",
"      Petersen J, Moore RM Jr, Kaczmarek RG, et al. The effects of reprocessing cuprophane and polysulfone dialyzers on beta 2-microglobulin removal from hemodialysis patients. Am J Kidney Dis 1991; 17:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/30\">",
"      Westhuyzen J, Foreman K, Battistutta D, et al. Effect of dialyzer reprocessing with Renalin on serum beta-2-microglobulin and complement activation in hemodialysis patients. Am J Nephrol 1992; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/31\">",
"      Cheung AK, Agodoa LY, Daugirdas JT, et al. Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. J Am Soc Nephrol 1999; 10:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/32\">",
"      Scott MK, Mueller BA, Sowinski KM, Clark WR. Dialyzer-dependent changes in solute and water permeability with bleach reprocessing. Am J Kidney Dis 1999; 33:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/33\">",
"      Sherman RA, Cody RP, Rogers ME, Solanchick JC. The effect of dialyzer reuse on dialysis delivery. Am J Kidney Dis 1994; 24:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/34\">",
"      Labib ME, Murawski J, Tabani Y, et al. Water permeability of high-flux dialyzer membranes after Renalin reprocessing. Kidney Int 2007; 71:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/35\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/36\">",
"      Howell ED, Perkins HA. Anti-N-like antibodies in the sera of patients undergoing chronic hemodialysis. Vox Sang 1972; 23:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/37\">",
"      Kaehny WD, Miller GE, White WL. Relationship between dialyzer reuse and the presence of anti-N-like antibodies in chronic hemodialysis patients. Kidney Int 1977; 12:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/38\">",
"      Pegues DA, Beck-Sague CM, Woollen SW, et al. Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 1992; 42:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/39\">",
"      Schoenfeld P, McLaughlin MD, Mendelson M. Heat disinfection of polysulfone hemodialyzers. Kidney Int 1995; 47:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/40\">",
"      Twardowski ZJ. Dialyzer reuse--part II: advantages and disadvantages. Semin Dial 2006; 19:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/41\">",
"      Pollak VE, Kant KS, Parnell SL, Levin NW. Repeated use of dialyzers is safe: long-term observations on morbidity and mortality in patients with end-stage renal disease. Nephron 1986; 42:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/42\">",
"      Held PJ, Pauly MV, Diamond L. Survival analysis of patients undergoing dialysis. JAMA 1987; 257:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/43\">",
"      Wing AJ, Brunner FP, Brynger HO, et al. Mortality and morbidity of reusing dialysers. A report by the registration committee of the European Dialysis and Transplant Association. Br Med J 1978; 2:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/44\">",
"      Feldman HI, Kinosian M, Bilker WB, et al. Effect of dialyzer reuse on survival of patients treated with hemodialysis. JAMA 1996; 276:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/45\">",
"      Collins AJ, Ma JZ, Constantini EG, Everson SE. Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993. J Am Soc Nephrol 1998; 9:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/46\">",
"      Kimmel PL, Mishkin GJ. Dialyzer reuse and the treatment of patients with end-stage renal disease by hemodialysis. J Am Soc Nephrol 1998; 9:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/47\">",
"      Ebben JP, Dalleska F, Ma JZ, et al. Impact of disease severity and hematocrit level on reuse-associated mortality. Am J Kidney Dis 2000; 35:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/48\">",
"      Port FK, Wolfe RA, Hulbert-Shearon TE, et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the usrds dialysis morbidity and mortality study. Am J Kidney Dis 2001; 37:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/49\">",
"      Collins AJ, Liu J, Ebben JP. Dialyser reuse-associated mortality and hospitalization risk in incident Medicare haemodialysis patients, 1998-1999. Nephrol Dial Transplant 2004; 19:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/50\">",
"      Lowrie EG, Li Z, Ofsthun N, Lazarus JM. Reprocessing dialysers for multiple uses: recent analysis of death risks for patients. Nephrol Dial Transplant 2004; 19:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/51\">",
"      Robinson BM, Feldman HI. Dialyzer reuse and patient outcomes: what do we know now? Semin Dial 2005; 18:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/52\">",
"      Fan Q, Liu J, Ebben JP, Collins AJ. Reuse-associated mortality in incident hemodialysis patients in the United States, 2000 to 2001. Am J Kidney Dis 2005; 46:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/53\">",
"      Bond TC, Nissenson AR, Krishnan M, et al. Dialyzer reuse with peracetic acid does not impact patient mortality. Clin J Am Soc Nephrol 2011; 6:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7096/abstract/54\">",
"      National Kidney Foundation report on dialyzer reuse. Task Force on Reuse of Dialyzers, Council on Dialysis, National Kidney Foundation. Am J Kidney Dis 1997; 30:859.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1863 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7096=[""].join("\n");
var outline_f6_59_7096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REPROCESSING TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rinsing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cleaning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Performance testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Disinfection and sterilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RATE OF REUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL CONSIDERATIONS WITH DIALYZER REUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infection risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Biochemical and immune system effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Loss of performance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GERMICIDE EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General problems with chemical disinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Heat disinfection of dialyzers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EFFECTS OF REUSE ON PATIENT MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NKF TASK FORCE POSITION PAPER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9911?source=related_link\">",
"      Biochemical mechanisms involved in blood-hemodialysis membrane interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10775?source=related_link\">",
"      Maintaining water quality for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_59_7097="Dip and plateau in constrictive pericarditis";
var content_f6_59_7097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Dip and plateau in constrictive pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemodynamic record of a patient with surgically proven constrictive pericarditis.",
"    <br>",
"     (A) Slow-paper-speed recording of high-gain left ventricular (LV) pressure and simultaneous right heart pullback from pulmonary capillary wedge (PCW) to pulmonary artery (PA), right ventricle (RV), and right atrium (RA).",
"     <br>",
"      (B) Fast-paper-speed recording of LV and simultaneous RV and RA pressure tracings. Note the increased and equal atrial and diastolic pressures, the prominent X and Y descents on the RA tracing, and the dip and plateau on the RV and LV tracings during longer diastoles.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       From: Hoit BD. Pericardial disease and pericardial heart disease. In: O'Rourke RA, ed. Stein's Internal Medicine, 5th Edition. St. Louis: Mosby-Year Book, 1998. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7097=[""].join("\n");
var outline_f6_59_7097=null;
var title_f6_59_7098="Overview of the non-acute management of ST elevation myocardial infarction";
var content_f6_59_7098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the non-acute management of ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/59/7098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7098/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7098/contributors\">",
"     Harold L Kennedy, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7098/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/59/7098/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7098/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7098/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/59/7098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/59/7098/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/59/7098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of an acute STEMI is made, the early management of the patient involves the simultaneous achievement of several goals including relief of ischemic pain, assessment of the hemodynamic state and correction of abnormalities that are present, initiation of reperfusion therapy with primary percutaneous coronary intervention (PCI) or fibrinolysis, and initiation of antithrombotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These early diagnostic and therapeutic interventions are followed by the initiation of short- and long-term interventions aimed at improving in-hospital and long-term outcomes. This topic will summarize the management of patients with acute STEMI in the hours and days following the very early decision making period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of the patient with a non-ST elevation or non-Q wave MI (NSTEMI) or with a complication of an acute MI (eg, cardiogenic shock, mitral regurgitation, ventricular septal defect) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"     \"Mechanical complications of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FURTHER MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker are usually given as soon as the diagnosis of STEMI is made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early initiation of the following therapies may be of benefit in patients hospitalized with STEMI. Many of them are useful long term. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Preparing for discharge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oral beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;An oral cardioselective beta blocker should be continued or begun if the patient has not received early, oral beta blocker therapy. Patients who did not receive a beta blocker during the first 24 hours because of early contraindications should be reevaluated for beta blocker candidacy.",
"   </p>",
"   <p>",
"    Most patients are continued on an oral beta blocker indefinitely. The efficacy of beta blocker therapy is related in part to the degree of heart rate slowing. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The concomitant use of beta blockers and angiotensin inhibitors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link&amp;anchor=H8#H8\">",
"     \"Beta blockers in the management of acute coronary syndrome\", section on 'LV dysfunction/heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates can be useful during the first 24 to 48 hours in patients with recurrent ischemia, hypertension, or heart failure. However, nitrates should be avoided in patients with a right ventricular myocardial infarction in whom the reduction in preload can lower the cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link&amp;anchor=H12#H12\">",
"     \"Right ventricular myocardial infarction\", section on 'Optimization of right ventricular preload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nitrate therapy after 48 hours is useful for the treatment of recurrent ischemia or heart failure as long as it does not preclude adequate therapy with agents proven to reduce mortality, such as beta blockers or ACE inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=see_link\">",
"     \"Nitrates in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nitrates used for this purpose include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    , or a transdermal nitroglycerine patch. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link&amp;anchor=H6#H6\">",
"     \"Nitrates in the management of stable angina pectoris\", section on 'Nitrate tolerance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Phosphodiesterase-5 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phosphodiesterase-5 inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    ) are contraindicated in patients taking nitrates because of the potential for exaggerated vasodilation and hypotension and an increased risk of MI or death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"     \"Sexual activity in patients with heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive statin therapy should be initiated as early as possible in all patients with an STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link&amp;anchor=H12124338#H12124338\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\", section on 'Statin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers primarily serve as adjunctive therapy in patients with ongoing or recurrent symptoms of ischemia despite optimal therapy with beta blockers (with or without nitrates), in patients who are unable to tolerate adequate doses of one or both of these agents, or in patients with rapid atrial fibrillation when beta blockers are contraindicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40469?source=see_link\">",
"     \"Calcium channel blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No calcium channel blocker has been shown to reduce mortality in acute STEMI, and in certain patients they may be harmful, such as those with evidence of HF, left ventricular dysfunction, or atrioventricular block.",
"   </p>",
"   <p>",
"    When a calcium channel blocker is used for the indications above, only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    are recommended in patients with STEMI. Immediate release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    is contraindicated because of the reflex sympathetic activation, tachycardia, and hypotension associated with its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link&amp;anchor=H10#H10\">",
"     \"Major side effects and safety of calcium channel blockers\", section on 'Increased mortality after acute MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second generation dihydropyridine calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    , appear to be safe in other forms of cardiovascular disease. Extrapolation from the results of these trials does not necessarily confirm that amlodipine or felodipine are safe in patients with an acute STEMI. Nonetheless, these agents, especially amlodipine, are often used when hypertension is not adequately controlled by other therapy of proven benefit (beta blockers and ACE inhibitors).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     In-hospital glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The correction of hyperglycemia has become standard care for hospitalized patients, including those with acute myocardial infarction (MI). However, whether control of hyperglycemia is sufficient to reduce morbidity and mortality is not proven at this time. The evidence upon which recommendations for glycemic control can be made and the specific recommendations are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Venous thromboembolism prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis for venous thromboembolism should be considered in medical patients who are immobilized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in medical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, many patients with STEMI are now ambulatory within 24 hours, particularly if they have received reperfusion therapy and have had uncomplicated courses. These patients do not require such prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H31#H31\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that in patients with uncomplicated STEMI, who will be at bed rest for less than 24 hours, venous thromboembolism prophylaxis is not necessary (unless indicated for some other reason). For STEMI patients in whom bed rest is anticipated for more than 24 hours and for whom anticoagulation is no longer required as part of the management of their acute coronary syndrome, we suggest low-dose UFH (5000 units every 8 to 12 hours), LMWH (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    2.5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    all given subcutaneously, until the patient is ambulatory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia can reduce the delivery of oxygen to the myocardium and, in a review of clinical trials of patients with a non-ST elevation ACS, the risk of cardiovascular mortality, nonfatal MI, or recurrent ischemia at 30 days was significantly increased in patients with a hemoglobin concentration below 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link&amp;anchor=H28#H28\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, studies evaluating the importance of anemia and the role of transfusion in the setting of an acute coronary syndrome (ACS) have reached differing conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unlikely that transfusion is beneficial for patients with an ACS who have a hemoglobin above 10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    but the benefits probably exceed the risks for patients with a hematocrit below 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/8\">",
"     8",
"    </a>",
"    ]. There are no published high quality data that can be used to formulate recommendations for the threshold for red blood cell transfusion in patients with an ACS. A 2012 systematic review of 10 studies (including one small randomized trial) of over 200,000 patients with either NSTEMI or STEMI found an increased rate of all-cause mortality associated with a strategy of blood transfusion compared to no transfusion (18.2 versus 10.2 percent; risk ratio 2.91, 95% CI 2.46-3.44) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/9\">",
"     9",
"    </a>",
"    ]. This association continued after multivariate analysis. However, the practical application of this study is limited as the authors did not perform an analysis stratified by baseline hemoglobin level.",
"   </p>",
"   <p>",
"    Individual patient characteristics such as the rate of blood loss and severity of myocardial ischemia need to be taken into account. We suggest transfusing red blood cells to maintain the hemoglobin &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    particularly when the anemia is acute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2013 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for the management of STEMI suggests that transfusion should be avoided unless the hemoglobin level is &lt;8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in patients",
"    <strong>",
"     without",
"    </strong>",
"    active ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gastrointestinal prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ACS who develop gastrointestinal bleeding (GI) after PCI have significantly worse outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=see_link&amp;anchor=H5971608#H5971608\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion of the primary prevention of gastrointestinal bleeding is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=see_link&amp;anchor=H5971641#H5971641\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECURRENT CHEST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent chest pain after STEMI is typically caused by either recurrent ischemia and reinfarction or by post",
"    <strong>",
"     -",
"    </strong>",
"    infarction pericarditis. Usually, recurrent chest pain within the first 12 hours of onset of MI is considered to be related to the original infarct and not evidence of reinfarction. Pericarditis is probably not responsible for significant chest discomfort in the first 24 hours.",
"   </p>",
"   <p>",
"    A somewhat separate issue, chest pain or silent ischemia on stress testing before or soon after discharge, is discussed below. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Stress testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Recurrent ischemia and reinfarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with an STEMI who have undergone apparently successful fibrinolysis by clinical criteria, early recurrence of ischemia (threatened reocclusion) has been observed in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], thrombotic coronary reocclusion in 5 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/12-14\">",
"     12-14",
"    </a>",
"    ], and reinfarction in 3 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Among patients treated with fibrinolysis, reinfarction occurs at a median of two to four days after therapy and is associated with increases in in-hospital and 30-day mortality compared to those patients without reinfarction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. As many patients who have undergone fibrinolysis are routinely referred for percutaneous coronary intervention (PCI), the frequency of recurrent ischemia after fibrinolysis is decreasing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent ischemia or reinfarction after primary PCI represents ischemia in a coronary distribution not revascularized or possible stent thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the first 18 hours of the initial MI, a recurrent elevation in cardiac biomarkers alone should",
"    <strong>",
"     not",
"    </strong>",
"    be relied upon to diagnose reinfarction, but should be accompanied by recurrent ST segment elevation on ECG and at least one other supporting criterion (such as recurrent chest pain or hemodynamic decompensation). For patients more than 18 hours from the initial MI, a biomarker rise and at least one additional criterion are sufficient for the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial medical management of recurrent ischemia after STEMI should include escalation of therapy with beta blockers and nitrates to decrease myocardial oxygen demand and reduce ischemia. Intravenous anticoagulation should be initiated if it is not already being administered. For patients with hemodynamic instability, poor left ventricular function, or a large area of myocardium at risk, insertion of an intraaortic balloon pump should also be considered.",
"   </p>",
"   <p>",
"    PCI is the treatment of choice for patients with recurrent ischemia. Patients with recurrent ST elevation can also be treated or retreated with fibrinolytic therapy. However, an invasive strategy of angiography and revascularization is usually preferred. Patients should",
"    <strong>",
"     not",
"    </strong>",
"    be retreated with streptokinase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Infarction pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pericarditis, generally defined as a pericardial friction rub with or without chest discomfort, may complicate the course of an acute MI. Chest pain is typically pleuritic. Pain in one or both trapezius ridges is especially consistent with the diagnosis. The evaluation and management of this complication are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=see_link&amp;anchor=H2#H2\">",
"     \"Pericardial complications of myocardial infarction\", section on 'Peri-infarction pericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREPARING FOR DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activity level in-hospital is determined by clinical status; most uncomplicated patients will be able to ambulate when the risk of bleeding from the arterial puncture site is low. Prior to discharge, the patient should undergo risk stratification, including noninvasive measurement of resting left ventricular function and possibly exercise testing (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Recurrent ischemia and reinfarction'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Other components of predischarge planning include counseling about changes in",
"    <span class=\"nowrap\">",
"     behavioral/lifestyle",
"    </span>",
"    (smoking cessation, dietary improvement, and cardiac rehabilitation) and appropriate medical therapy to reduce the risk for further ischemic episodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Early discharge after an uncomplicated MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early discharge (within three to five days) of a patient undergoing reperfusion who has had an uncomplicated STEMI (no angina or evidence of ischemia, bleeding, HF, or arrhythmia 72 hours after the event) is considered safe [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late risk stratification is performed before or sometimes after discharge. The main components are measurement of the left ventricular ejection fraction and, in many patients, stress testing to detect possible residual ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Evaluation of LV function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of resting left ventricular function is an important part of risk stratification in patients with acute MI and was given a strong recommendation in the 2013 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for the management of STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Patients with left ventricular systolic dysfunction have increased mortality at six months and one year (",
"    <a class=\"graphic graphic_figure graphicRef75743 graphicRef68071 \" href=\"UTD.htm?1/30/1519\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The increase in mortality is most pronounced in the 8 to 10 percent of patients with a left ventricular ejection fraction (LVEF) &le;30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of a specific indication (eg, HF or suspected mechanical complication), the LVEF is usually measured before discharge. However, early measurements of LVEF may be misleading, since improvement in LVEF, beginning within three days and largely complete by 14 days, is common in patients who are reperfused, a presumed reflection, at least in part, of recovery from myocardial stunning [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple imaging techniques for assessing left ventricular function are available and each has equivalent prognostic value in the post-MI patient. In general, echocardiography should be used for routine assessment of LVEF after acute MI. It has the added advantage of detecting other factors that can be associated with a worse prognosis such as diastolic dysfunction, concurrent right ventricular dysfunction, left atrial enlargement, mitral regurgitation, and left ventricular thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=see_link\">",
"     \"Role of echocardiography in acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=see_link\">",
"     \"Left ventricular thrombus after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     Stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stress test, usually with exercise, is typically performed after STEMI to detect residual ischemia. Stress testing also permits assessment of the exercise capacity needed for the cardiac rehabilitation exercise prescription and can, in some patients, identify arrhythmias. While the prognostic value of stress testing has declined in the reperfusion era, such an assessment is standard practice in the United States and required of patients referred to a cardiac rehabilitation program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link&amp;anchor=H35#H35\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\", section on 'Stress testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Predischarge stress testing to detect residual ischemia is generally",
"    <strong>",
"     not",
"    </strong>",
"    performed in patients who have undergone PCI or CABG and have been",
"    <strong>",
"     fully",
"    </strong>",
"    revascularized (eg, single vessel disease and successful PCI). Such patients often undergo exercise testing a few weeks or more after discharge as part of a cardiac rehabilitation program or for activity counseling.",
"   </p>",
"   <p>",
"    Patients who have undergone partial revascularization or no revascularization, in contrast, are candidates for low level predischarge stress testing, which appears to be safe if:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient has undergone in-hospital cardiac rehabilitation",
"     </li>",
"     <li>",
"      There have not been symptoms of HF or recurrent angina",
"     </li>",
"     <li>",
"      The ECG has been stable for 48 to 72 hours prior to the exercise test",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stress testing should",
"    <strong>",
"     not",
"    </strong>",
"    be performed in patients with unstable postinfarction angina, decompensated HF, or life-threatening cardiac arrhythmias.",
"   </p>",
"   <p>",
"    The appropriate stress protocol varies with physician preferences, patient characteristics, and local laboratory expertise. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link&amp;anchor=H37#H37\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\", section on 'Stress protocol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accurate interpretation cannot be achieved in patients with baseline ECG abnormalities such as left bundle branch block, left ventricular hypertrophy with ST-T wave changes, ventricular preexcitation, or ventricular pacing. In such patients, either exercise echocardiography or exercise radionuclide myocardial perfusion imaging can be performed. Pharmacologic stress is required in patients who cannot exercise, although such modalities provide less information than exercise testing because they are not able to assess functional capacity (",
"    <a class=\"graphic graphic_algorithm graphicRef71324 \" href=\"UTD.htm?26/52/27470\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with symptomatic ischemia on postinfarct stress testing, we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary angiography followed by revascularization if appropriate is performed in patients with noninvasive evidence suggesting a moderate to large amount of myocardium at risk. Examples include ischemia during stage I or II of the Bruce protocol, a hypotensive blood pressure response or symptoms of pulmonary congestion, more than 2 mm of ST segment depression, or imaging studies suggesting involvement of either a large portion of the anterior wall or showing multiple areas of ischemia.",
"     </li>",
"     <li>",
"      Patients with only mild ischemia can be continued on medical therapy alone, but patient preference may be important.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of silent ischemia detected on stress testing is similar and discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link&amp;anchor=H16#H16\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\", section on 'Post-MI ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chronic anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy following STEMI can reduce reinfarction and cerebrovascular accidents and may reduce mortality following acute MI. The discussion of the indications for chronic anticoagulation after MI is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20425?source=see_link\">",
"     \"Chronic anticoagulation after acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of implantable cardioverter defibrillators after MI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of late arrhythmias is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link&amp;anchor=H38#H38\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Late arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H427106064\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend influenza and pneumococcal vaccination as part of a comprehensive secondary prevention program in adults with coronary and other atherosclerotic vascular diseases. If indicated, we suggest vaccination for these during hospitalization for an acute coronary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H775072460#H775072460\">",
"     \"Seasonal influenza vaccination in adults\", section on 'High-priority groups'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Return to activities",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that patients be counseled about returning to prior activities. The majority of patients who remain asymptomatic after an uncomplicated acute MI can probably return to prior nonphysical activities, including work, safely within two weeks, although few data are available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daily physical activity, such as walking, should be encouraged; the intensity of physical activity can be increased according to the cardiac rehabilitation plan.",
"     </li>",
"     <li>",
"      When sexual activity can be safely resumed is dependent upon a number of factors including whether or not the patient has been revascularized and, if not, if there is ischemia on stress testing (",
"      <a class=\"graphic graphic_table graphicRef71511 \" href=\"UTD.htm?43/3/44092\">",
"       table 1",
"      </a>",
"      ). An important caveat is that phosphodiesterase-5 inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      ) cannot be taken within 24 to 48 hours of a nitrate. These issues are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"       \"Sexual activity in patients with heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Driving can begin a week after discharge if the patient is judged to be in compliance with individual state laws.",
"     </li>",
"     <li>",
"      Since commercial aircrafts are pressurized to 7500 to 8000 feet, air travel should be undertaken only by stable patients (without a fear of flying) within the first two weeks and then only as long as they travel with companions, carry sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , and request airport transportation to avoid rushing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link&amp;anchor=H17#H17\">",
"       \"High altitude, air travel, and heart disease\", section on 'Air travel'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with a complicated MI, return to usual activities should be delayed by two to three weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DISCHARGE MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate medical therapy can reduce the risk of subsequent ischemic events and mortality in patients who have had an acute MI. In addition to the interventions discussed in this section, beta blockers, statins, nitrates, and calcium channel blockers may be useful long term and are discussed above. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Further medical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Medications upon discharge from the hospital should include those important for risk reduction, including antiplatelet drugs, a beta blocker, a statin, and possibly an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Antiplatelet drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of an absolute contraindication,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is recommended indefinitely in all patients who have had an acute MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H20#H20\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Dosing and cardiovascular benefit'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H12#H12\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Secondary prevention of CVD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thienopyridine therapy is indicated in all patients after STEMI, for at least one year, regardless of the reperfusion strategy. The specific recommendations for the duration of therapy after MI or stent placement are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H18#H18\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2013 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for the management of STEMI gave a strong recommendation for chronic therapy with an angiotensin converting enzyme (ACE) inhibitor (unless contraindicated) for patients with STEMI with anterior location, heart failure, or left ventricular ejection fraction less than or equal to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A weak recommendation for ACE inhibitor was made for all patients with STEMI. An angiotensin receptor blocker was recommended for those who are intolerant of ACE inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angiotensin receptor blockers (ARBs) and ACE inhibitors are of equal efficacy in patients with recent MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H17#H17\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'Comparison to ACE inhibitor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ARB should",
"    <strong>",
"     not",
"    </strong>",
"    be given in addition to an ACE inhibitor in the immediate post-MI setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2013 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for the management of STEMI gave a strong recommendation for chronic therapy with an aldosterone antagonist (unless contraindicated) for patients with STEMI who are receiving an ACE inhibitor and a beta blocker and who have a left ventricular ejection fraction less than or equal to 40 percent and either heart failure or diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy should be begun before discharge, since a mortality benefit is seen within 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/32\">",
"     32",
"    </a>",
"    ]. The serum potassium should be monitored closely during treatment. Although uncommon, life-threatening hyperkalemia can occur due to the combination of aldosterone inhibition, reduced aldosterone secretion associated with ACE inhibitor therapy, and a progressive decline in renal perfusion induced due to HF. Elderly patients with renal insufficiency are at greatest risk. The use of aldosterone antagonists is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H4#H4\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Eplerenone in EPHESUS trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     RISK FACTOR MODIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factor modification using",
"    <span class=\"nowrap\">",
"     behavioral/lifestyle",
"    </span>",
"    changes such as dietary modification, increase in activity level, and smoking cessation are associated with better outcomes after acute coronary syndromes. Patient education should be given at the time of discharge and referral to a cardiac rehabilitation program should be made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link&amp;anchor=H22#H22\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Therapeutic lifestyle changes'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H38\">",
"     'Cardiac rehabilitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation reduces the risk of recurrent MI. In one study of 564 postinfarction patients, for example, the risk of recurrent infarction fell by 50 percent within one year of smoking cessation and normalized to that of nonsmokers within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend education about smoking cessation during hospitalization and referral to a smoking cessation program or outpatient cardiac rehabilitation program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link&amp;anchor=H13311131#H13311131\">",
"     \"Pharmacotherapy for smoking cessation in adults\", section on 'Nicotine replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the issue of whether nicotine replacement can be started during hospitalization has not been well studied. The safety of this approach was evaluated in a retrospective analysis of 194 smokers admitted with an ACS who received transdermal nicotine replacement therapy during their hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/59/7098/abstract/34\">",
"     34",
"    </a>",
"    ]. Compared to a propensity matched cohort, there was no difference in mortality at 7 and 30 days and at one year in patients started on nicotine replacement in-hospital.",
"   </p>",
"   <p>",
"    We suggest cautious initiation of nicotine replacement during hospitalization for those patients with ACS in whom the benefits appear to outweigh the risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Long term glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend a goal HbA1c of less than 7 percent, which is consistent with the general treatment goal for patients with type 2 diabetes. The supporting evidence and treatment goals are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Degree of glycemic control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thiazolidinediones have been used in the treatment of patients with diabetes mellitus. A concern has been raised about the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    in patients with CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension should be treated in patients who have had an MI. The optimal goal blood pressure and choice of antihypertensive drugs in such patients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good dietary habits and use of a prudent diet can reduce the risk of coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in activity level in patients with established cardiovascular disease is associated with better outcomes. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Stress management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial stress factors are associated with a poor prognosis after acute MI, and reducing emotional stress may improve outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=see_link\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Cardiac rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multifactorial cardiac rehabilitation, which includes efforts to address all of the above issues, can produce significant long-term reductions in both total and cardiovascular mortality. All patients should be considered for referral to a cardiac rehabilitation facility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=see_link\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with an NSTEMI have a lower in-hospital mortality than those with an STEMI, but a similar or perhaps worse long-term outcome. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41769?source=see_link\">",
"     \"Prognosis after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       \"Patient information: Heart attack (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/6/37987?source=see_link\">",
"       \"Patient information: Heart attack recovery (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=see_link\">",
"       \"Patient information: Medicines after a heart attack (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       \"Patient information: Heart attack (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=see_link\">",
"       \"Patient information: Heart attack recovery (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with ST elevation myocardial infarction (STEMI), early diagnostic and therapeutic interventions, such as antiplatelet therapy and emergency reperfusion, are associated with improved early outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the patient has been stabilized and these early interventions carried out, other short- and long-term interventions aimed at improving both in-hospital and long-term outcomes need to be considered.",
"   </p>",
"   <p>",
"    The following interventions are beneficial in the majority of patients with STEMI who have undergone early interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Oral beta blockers'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Long-term dual antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and a thienopyridine (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Antiplatelet drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Statins (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Statin therapy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Aggressive management of recurrent myocardial ischemia or infarction (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Recurrent chest pain'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      ACE inhibitors in patients with diabetes, heart failure, a left ventricular ejection fraction &lt;40 percent, and hypertension (see",
"      <a class=\"local\" href=\"#H29\">",
"       'Angiotensin inhibition'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Long-term risk stratification with assessment of left ventricular function and either diagnostic coronary arteriography or pre-discharge stress testing. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major modifiable risk factors for coronary artery disease (smoking, hypertension, diabetes, and dyslipidemia) need to be evaluated and corrected as necessary. A long-term plan for their control needs to be discussed with the patient; referral to an outpatient cardiac rehabilitation program is useful for this purpose. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Risk factor modification'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/1\">",
"      Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/2\">",
"      Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/3\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/4\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/5\">",
"      Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/6\">",
"      Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/7\">",
"      H&eacute;bert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001; 29:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/8\">",
"      H&eacute;bert PC, Fergusson DA. Do transfusions get to the heart of the matter? JAMA 2004; 292:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/9\">",
"      Chatterjee S, Wetterslev J, Sharma A, et al. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med 2013; 173:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/10\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/11\">",
"      Langer A, Krucoff MW, Klootwijk P, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998; 31:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/12\">",
"      Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/13\">",
"      Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990; 82:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/14\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/15\">",
"      Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003; 42:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/16\">",
"      D&ouml;nges K, Schiele R, Gitt A, et al. Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]). Am J Cardiol 2001; 87:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/17\">",
"      Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/18\">",
"      Barbash GI, Birnbaum Y, Bogaerts K, et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. Circulation 2001; 103:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/19\">",
"      Topol EJ, Burek K, O'Neill WW, et al. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med 1988; 318:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/20\">",
"      Mark DB, Sigmon K, Topol EJ, et al. Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry. Circulation 1991; 83:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/21\">",
"      Bogaty P, Dumont S, O'Hara GE, et al. Randomized trial of a noninvasive strategy to reduce hospital stay for patients with low-risk myocardial infarction. J Am Coll Cardiol 2001; 37:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/22\">",
"      Newby LK, Eisenstein EL, Califf RM, et al. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000; 342:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/23\">",
"      Burns RJ, Gibbons RJ, Yi Q, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002; 39:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/24\">",
"      Zaret BL, Wackers FJ, Terrin ML, et al. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. J Am Coll Cardiol 1995; 26:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/25\">",
"      Sheehan FH, Doerr R, Schmidt WG, et al. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol 1988; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/26\">",
"      Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001; 134:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/27\">",
"      Nijland F, Kamp O, Karreman AJ, et al. Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: a serial Doppler echocardiographic study. J Am Coll Cardiol 1997; 30:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/28\">",
"      M&oslash;ller JE, S&oslash;ndergaard E, Poulsen SH, Egstrup K. Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: a serial color M-mode Doppler echocardiographic study. J Am Coll Cardiol 2000; 36:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/29\">",
"      Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol 2002; 39:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/30\">",
"      Moller JE, Hillis GS, Oh JK, et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 2003; 107:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/31\">",
"      Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001; 103:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/32\">",
"      Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/33\">",
"      Wilhelmsson C, Vedin JA, Elmfeldt D, et al. Smoking and myocardial infarction. Lancet 1975; 1:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/59/7098/abstract/34\">",
"      Meine TJ, Patel MR, Washam JB, et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005; 95:976.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 67 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-FFF4911520-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7098=[""].join("\n");
var outline_f6_59_7098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FURTHER MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oral beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nitrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Phosphodiesterase-5 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Statin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      In-hospital glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Venous thromboembolism prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gastrointestinal prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECURRENT CHEST PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Recurrent ischemia and reinfarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Infarction pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREPARING FOR DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Early discharge after an uncomplicated MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Evaluation of LV function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Stress testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chronic anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H427106064\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Return to activities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DISCHARGE MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Antiplatelet drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      RISK FACTOR MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Long term glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Stress management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Cardiac rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/67\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/67|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/52/27470\" title=\"algorithm 1\">",
"      Choice stress test modality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/67|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/2/29741\" title=\"figure 1A\">",
"      LVEF predicts six-month mortality after STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/50/38701\" title=\"figure 1B\">",
"      LVEF predicts one-year mortality after STEMI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/67|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/3/44092\" title=\"table 1\">",
"      Management sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40469?source=related_link\">",
"      Calcium channel blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20425?source=related_link\">",
"      Chronic anticoagulation after acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=related_link\">",
"      Efficacy of cardiac rehabilitation in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=related_link\">",
"      Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=related_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=related_link\">",
"      Nitrates in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=related_link\">",
"      Nitrates in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=related_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/6/37987?source=related_link\">",
"      Patient information: Heart attack recovery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=related_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=related_link\">",
"      Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=related_link\">",
"      Pharmacotherapy for smoking cessation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41769?source=related_link\">",
"      Prognosis after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=related_link\">",
"      Role of echocardiography in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_59_7099="Cytokine assays";
var content_f6_59_7099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=28\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=28\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cytokine assays",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bioassays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensitive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less specific",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibitors interfere with assay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunoassays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less sensitive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very specific",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid factors, soluble receptors can interfere",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Messenger RNA assays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complex procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not always correlated with cytokine protein release",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7099=[""].join("\n");
var outline_f6_59_7099=null;
var title_f6_59_7100="Altered dental care delivery";
var content_f6_59_7100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions that can impede the delivery of dental treatment in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Effect on dental care delivery",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dental management",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cerebral palsy",
"      </td>",
"      <td>",
"       Wheelchair access; immobility; uncontrolled movements; reflex problems",
"      </td>",
"      <td>",
"       Treatment in wheelchair; use of restraints; use of pharmacologic means to manage movement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscular dystrophy",
"      </td>",
"      <td>",
"       Wheelchair access; immobility; risk of aspiration; lack of muscle control",
"      </td>",
"      <td>",
"       Treatment in wheelchair; use of restraints and supports",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mental retardation",
"      </td>",
"      <td>",
"       Inability to cooperate",
"      </td>",
"      <td>",
"       Behavior modification; use of pharmacologic agents to manage behavior",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autism",
"      </td>",
"      <td>",
"       Inability to cooperate",
"      </td>",
"      <td>",
"       Behavior modification; use of pharmacologic agents to manage behavior",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Attention deficit hyperactivity disorder",
"      </td>",
"      <td>",
"       Short attention span",
"      </td>",
"      <td>",
"       Behavior modification; treatment when medicated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sensory disorders",
"      </td>",
"      <td>",
"       Communication difficulties",
"      </td>",
"      <td>",
"       Use of adjunctive communication means/interpreters; use of pharmacologic agents to manage behavior",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spinal cord injury",
"      </td>",
"      <td>",
"       Wheelchair bound; pressure sores; autonomic dysreflexia",
"      </td>",
"      <td>",
"       Treatment in wheelchair; positioning/stabilizing techniques",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spina bifida",
"      </td>",
"      <td>",
"       Intellectual impairment; wheelchair bound; positioning difficulties",
"      </td>",
"      <td>",
"       Behavior modification; treatment in wheelchair; positioning and stabilizing techniques",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Casamassimo PS. Pediatr Clin North Am 2000; 47:1149. Copyright &copy;2000 W.B. Saunders Co.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7100=[""].join("\n");
var outline_f6_59_7100=null;
var title_f6_59_7101="Food-borne diseases V";
var content_f6_59_7101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-V",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Chemical (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Marine toxins (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Scombroid toxin (histamine)",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        1 min-3 hrs, usually &lt;1 hr",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Flushing, dizziness, burning of mouth and throat, headache, gastrointestinal symptoms, urticaria, and generalized pruritus",
"       </td>",
"       <td class=\"sublist_other\">",
"        Demonstration of histamine in epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Clinical syndrome among persons who have eaten type of fish previously associated with histamine fish poisoning (eg, mahi-mahi or fish of order Scomboidei)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Paralytic or neurotoxic shellfish poison",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        30 min-3 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Paresthesia of lips, mouth or face, and extremities; intestinal symptoms or weakness, including respiratory difficulty",
"       </td>",
"       <td class=\"sublist_other\">",
"        Detection of toxin in epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Detection of large numbers of shellfish-poisoning-associated species of dinoflagellates in water from which epidemiologically implicated mollusks are gathered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Puffer fish, tetrodotoxin",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        10 min-3 hrs, usually 10-45 mins",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Paresthesia of lips, tongue, face, or extremities, often following numbness; loss of proprioception or \"floating\" sensations",
"       </td>",
"       <td class=\"sublist_other\">",
"        Demonstration of tetrodotoxin in epidemiologically implicated fish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Clinical syndrome among persons who have eaten puffer fish",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Heavy metals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Antimony",
"       </td>",
"       <td rowspan=\"6\">",
"        5 min-8 hrs, usually &lt;1 hr",
"       </td>",
"       <td rowspan=\"6\">",
"        Vomiting, often metallic taste",
"       </td>",
"       <td rowspan=\"6\">",
"        Demonstration of high concentration of metal in epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cadmium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Copper",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Zinc",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Monosodium glutamate (MSG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3 mins-2 hrs, usually &lt;1 hr",
"       </td>",
"       <td>",
"        Burning sensation in chest, neck, abdomen, or extremities; sensation of lightness and pressure over face or heavy feeling in chest",
"       </td>",
"       <td>",
"        Clinical syndrome among persons who have eaten food containing MSG (ie, usually &ge;1.5 g MSG)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7101=[""].join("\n");
var outline_f6_59_7101=null;
var title_f6_59_7102="Intermittent transdermal NTG";
var content_f6_59_7102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Efficacy of intermittent transdermal nitroglycerin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 265px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Within day changes on day 1 and day 30 in treadmill walking time to moderate angina in 291 patients with stable angina treated with placebo or increasing doses of transdermal nitroglycerin for 12 hours per day. Transdermal NTG was associated with a dose-dependent increase in exercise tolerance that attenuated over the course of 12 hours but was maintained over the long term.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Parker JO, Amies MH, Hawkinson RW, et al. Circulation 1995; 91:1368.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7102=[""].join("\n");
var outline_f6_59_7102=null;
var title_f6_59_7103="Depressive episodes over five-years by age group";
var content_f6_59_7103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F60472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F60472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Mean proportions of weeks in depressive episodes over five-year periods by age group",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 370px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Height of rectangle indicates the mean proportion, and error bar indicates +/- 1.00 standard error.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Coryell W, Solomon D, Leon A, et al. Does major depressive disorder change with age? Psychol Med 2009; 39:1689. Copyright &copy; 2009 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_59_7103=[""].join("\n");
var outline_f6_59_7103=null;
